[Therapeutical targets for revert liver fibrosis]. / Blancos terapéuticos potenciales para revertir la cirrosis hepática.
Rev Med Chil
; 135(6): 783-91, 2007 Jun.
Article
en Es
| MEDLINE
| ID: mdl-17728907
Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications: portal hypertension, liver failure, hepatic encephalopathy, and hepatocellular carcinoma and others. Efficient and well-tolerated antifibrotic drugs are still lacking, and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Efforts over the past decade have mainly focused on fibrogenic cells generating the scarring response, although promising data on inhibition of parenchymal injury or reduction of liver inflammation have also been obtained. A large number of approaches have been validated in culture studies and in animal models, and several clinical trials are underway or anticipated for a growing number of molecules. This review highlight recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hígado
/
Cirrosis Hepática
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
Es
Revista:
Rev Med Chil
Año:
2007
Tipo del documento:
Article
Pais de publicación:
Chile